Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Anaplastic thyroid carcinoma
Immunohistochemistry
Medullary thyroid carcinoma
Poorly differentiated thyroid carcinoma
TIGIT
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
15 Aug 2022
15 Aug 2022
Historique:
received:
26
02
2022
accepted:
29
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Immune checkpoint proteins have not been fully examined in follicular cell-derived thyroid carcinoma and medullary thyroid carcinoma (MTC). Anaplastic thyroid carcinoma (ATC) is one of the most aggressive carcinomas. Even multimodal treatment does not result in favorable clinical outcomes for patients with ATC. Anti-tumor immunity has therefore been highlighted as having therapeutic promise for ATC. We examined a novel immune checkpoint receptor, T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT), in variable thyroid lesions: adenomatous goiter, follicular adenoma, and thyroid carcinoma (TC) using immunohistochemistry (IHC). Our IHC results showed that TIGIT expression was detected in cancer cells of MTC and high-grade TC: poorly differentiated thyroid carcinoma (PDTC) and ATC. Neoplastic cells were positive for TIGIT in four of five MTCs (80.0%), 17 of 31 ATCs (54.8%) and in 3 of 12 PDTCs (25.0%). TIGIT was not detected in any adenomatous goiters, thyroid benign tumors, or differentiated thyroid carcinoma (DTCs). Intriguingly, ATC cells showing pleomorphic/giant cell features were positive for TIGIT, while ATC cells with other cell morphologies lacked the immunoreactivity. Intra-tumoral immune cell was inclined to be enriched in TIGI-positive ATC. Although coexisting papillary thyroid carcinoma (PTC) components demonstrated high-grade microscopic features, neither the PTC nor follicular thyroid carcinoma (FTC) components expressed TIGT in any composite ATCs. TIGIT was immunohistochemically found in MTC with high frequency and partially in high-grade TC. TIGIT expression in cancer cells may be beneficial for a potential utility in MTC and a subset of high-grade TC, especially ATC therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint proteins have not been fully examined in follicular cell-derived thyroid carcinoma and medullary thyroid carcinoma (MTC). Anaplastic thyroid carcinoma (ATC) is one of the most aggressive carcinomas. Even multimodal treatment does not result in favorable clinical outcomes for patients with ATC. Anti-tumor immunity has therefore been highlighted as having therapeutic promise for ATC.
METHODS
METHODS
We examined a novel immune checkpoint receptor, T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT), in variable thyroid lesions: adenomatous goiter, follicular adenoma, and thyroid carcinoma (TC) using immunohistochemistry (IHC).
RESULTS
RESULTS
Our IHC results showed that TIGIT expression was detected in cancer cells of MTC and high-grade TC: poorly differentiated thyroid carcinoma (PDTC) and ATC. Neoplastic cells were positive for TIGIT in four of five MTCs (80.0%), 17 of 31 ATCs (54.8%) and in 3 of 12 PDTCs (25.0%). TIGIT was not detected in any adenomatous goiters, thyroid benign tumors, or differentiated thyroid carcinoma (DTCs). Intriguingly, ATC cells showing pleomorphic/giant cell features were positive for TIGIT, while ATC cells with other cell morphologies lacked the immunoreactivity. Intra-tumoral immune cell was inclined to be enriched in TIGI-positive ATC. Although coexisting papillary thyroid carcinoma (PTC) components demonstrated high-grade microscopic features, neither the PTC nor follicular thyroid carcinoma (FTC) components expressed TIGT in any composite ATCs.
CONCLUSION
CONCLUSIONS
TIGIT was immunohistochemically found in MTC with high frequency and partially in high-grade TC. TIGIT expression in cancer cells may be beneficial for a potential utility in MTC and a subset of high-grade TC, especially ATC therapy.
Identifiants
pubmed: 35971106
doi: 10.1186/s12902-022-01113-4
pii: 10.1186/s12902-022-01113-4
pmc: PMC9377113
doi:
Substances chimiques
Immunoglobulins
0
Receptors, Immunologic
0
TIGIT protein, human
0
Tyrosine
42HK56048U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
204Informations de copyright
© 2022. The Author(s).
Références
J Clin Endocrinol Metab. 2021 Jan 1;106(1):120-132
pubmed: 33000173
Gland Surg. 2015 Feb;4(1):44-51
pubmed: 25713779
Endocr Relat Cancer. 2008 Dec;15(4):1069-74
pubmed: 18719091
Semin Diagn Pathol. 2020 Sep;37(5):248-256
pubmed: 32624319
Oncotarget. 2016 Mar 29;7(13):17194-211
pubmed: 26943572
J Clin Oncol. 2020 Aug 10;38(23):2620-2627
pubmed: 32364844
BMC Cancer. 2018 Dec 4;18(1):1209
pubmed: 30514251
Cancer Res. 2017 Nov 15;77(22):6375-6388
pubmed: 28883004
Endocr Relat Cancer. 2017 Feb;24(2):97-106
pubmed: 28093480
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
Int J Biol Markers. 2020 Sep;35(3):50-58
pubmed: 32686562
Clin Exp Immunol. 2020 May;200(2):108-119
pubmed: 31828774
Virchows Arch. 2020 Mar;476(3):431-437
pubmed: 31732814
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
PLoS One. 2011;6(7):e22567
pubmed: 21811634
J Am Acad Dermatol. 2019 Jul;81(1):219-227
pubmed: 30880064
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575
pubmed: 30882858
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 8;7(3):
pubmed: 32269065
Mol Med Rep. 2019 Oct;20(4):3773-3781
pubmed: 31485637
Endocr Pathol. 2014 Mar;25(1):21-9
pubmed: 24343523
Int J Cancer. 2005 Nov 20;117(4):538-50
pubmed: 15912538
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1943-1950
pubmed: 28324060
Cancer Res. 2016 Oct 1;76(19):5696-5706
pubmed: 27503932
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066
Am J Surg Pathol. 2007 Aug;31(8):1256-64
pubmed: 17667551
Thyroid. 2022 Aug;32(8):926-936
pubmed: 35583228
J Immunother Cancer. 2018 Jul 11;6(1):68
pubmed: 29996921
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Int Immunopharmacol. 2020 Mar;80:106198
pubmed: 31954274
J Exp Clin Cancer Res. 2021 Jan 7;40(1):22
pubmed: 33413561